Test-bolus versus bolus-tracking in the timing of hepatic arterial phase at contrast-enhanced magnetic resonance imaging in patients with hepatocellular carcinoma

Emilio Quaia*
Department of Medical, Surgical and Health Sciences, Operative Unit of Radiology, Cattinara Hospital, Italy

Abstract
Aim: To evaluate test-bolus versus bolus-tracking in the timing of hepatic arterial phase at contrast-enhanced magnetic resonance (MR) imaging in patients with hepatocellular carcinoma (HCC).

Methods: Eighteen patients with HCC were scanned by contrast-enhanced MR imaging with a delay time for the hepatic arterial phase calculated by test - bolus (n=9 patients) or bolus – tracking (n=9 patients).

Results: Test-bolus and bolus-tracking techniques did not differ in SNR (301.2 ± 154.54 vs. 330.77 ± 240.75; P=0.89) and CNR (24.5 ± 18.74 vs. 19.24 ± 13.67; P=0.89).

Conclusions: Test - bolus vs bolus - tracking did not differ in the timing of hepatic arterial phase in patients with HCC.

Introduction
Hypervascularity on hepatic arterial phase after contrast injection is one of the essential feature for the diagnosis of HCC according to the American Association for the Study of Liver Disease (ASL) [1] and the European Association for the study of the liver (EASL) [2] even though it is a transient phenomenon, and errors of only a few seconds during the image acquisition on hepatic arterial phase may determine a reduced diagnostic confidence and accuracy. Anyway, the determination of the precise timing of optimal contrast enhancement for detection of hepatocellular carcinoma (HCC) is technically challenging because this timing is affected by the patient’s circulation, the contrast injection protocol, and the imaging protocol.

Two methods - arbitrary fixed delay and test - bolus - have been used traditionally to determine the delay time from the start of contrast injection for the hepatic arterial phase at MR imaging. With the arbitrary fixed delay method, MR imaging is initiated 15–20 seconds after the start of the injection. This technique does not take into account injection- or patient-related variables. More properly, with the test-bolus method, 1–2 mL of contrast medium are injected and simultaneous rapid and repetitive MR imaging at one level is performed during free breathing to determine the time to peak aortic enhancement. The delay time is calculated on the basis of the time of peak aortic enhancement, injection volume, and rate. While considered the most accurate, this method requires additional imaging and calculations.

A further method corresponds to real-time bolus-tracking providing hepatic arterial phase images tailored to an individual patient’s cardiac output and peripheral bloodstream kinetic. A real time bolus-triggered method includes breath-hold instructions initiated as the contrast bolus reaches the celiac trunk (trigger point), and imaging initiated at an 5–10 s delay from the trigger point. This method is very used despite it presents some dependence on the operator’s subjective assessment of the contrast arrival in the abdominal aorta.

To our knowledge, only few previous studies [3-5] have been conducted to evaluate the optimal acquisition delay for dynamic contrast-enhanced multiphase MR imaging of the liver and HCC even though no further study compared test - bolus and bolus - tracking techniques.

The aim of this study was to evaluate test-bolus versus bolus-tracking in the timing of hepatic arterial phase at contrast-enhanced MR imaging in patients with HCC.

Materials and methods

Patients
The institutional review board of our hospital approved this single-centre prospective observational study. All patients provided informed content.

We included all patients who met the following inclusion criteria: biopsy-proven diagnosis of liver cirrhosis due to type B, type C, or alcoholic hepatitis; from one to four hypervascular nodules (diameter,
2-4cm; mean ± SD, 3.5 ± 1.2) suspected for HCC at contrast-enhanced CT and referred to contrast-enhanced abdominal MR imaging to improve the diagnostic confidence in the characterization of the dominant HCC nodule(s) or to identify additional nodules; no history of hepatic surgery or thermal ablation or chemoembolization; absence of renal failure (serum creatinine concentration < 1.5 mg/dL); contraindication to use of gadolinium-based contrast material. We initially included 25 patients while seven patients were excluded: three had tumor thrombi in the central portal vein, and four had numerous tumors involving the entire liver that may have changed hepatic hemodynamics.

Thus the final study sample consisted in 18 patients (8 male and 10 female; mean age, 66 years ± 12; body weight range, 33–69 kg; mean, 55.0 ± 8.4 [SD] kg). The age range of men was 48–88 years (mean, 67.5 years), and that of the women was 52–85 years (mean, 71.0 years). The definitive diagnosis of HCC was based on histology (n=2), histopathologic evidence after hepatic surgery (n = 3), on imaging follow-up based on contrast-enhanced dynamic CT showing an increase in tumor size within 3 months (n = 2), or on typical enhancement pattern on contrast-enhanced MR imaging (n=11 patients) based on EASL [1] or ASL criteria [2].

MR imaging

The MR imaging examination was performed within one month from contrast-enhanced CT using a superconducting magnet operating at 1.5 T (Achieva, 1.5T release 2.1.3.4, Philips Healthcare, Best, The Netherlands) with a peak gradient amplitude of 30 mT/m and a peak slew rate of 150 T/m/sec. Images were acquired in the transverse plane with a combined four-channel anteroposterior phased-array surface coil. Parallel imaging with a sensitivity-encoding (SENSE) technique with a factor of 1.5 – 1.7 was employed. A three-quarter field of view was used in the phase-encoding direction. Presaturation pulses were applied above and below the imaging volume to diminish flow artifacts.

Parallel imaging with a sensitivity-encoding (SENSE) technique was used in the phase-encoding direction. Presaturation pulses were applied above and below the imaging volume to diminish flow artifacts.

The baseline MR imaging examination included a breath-hold fast spin-echo T2-weighted MR imaging sequence, a fat-suppressed T2-weighted sequence, a T1-weighted in-phase and out-of-phase sequence, and a fast-field echo T2-weighted sequence. Dynamic MR imaging was performed before and after gadobenate dimeglumine (Gd-BOPTA, 0.1 mmol/kg; 2 mL/sec) injection via a forearm or antecubital vein at 2 mL/sec through a 18-gauge intravenous catheter employing an automated agent injection.

The same two readers, consensually, calculated the signal-to-noise ratio (SNR = mean SI liver / SD) and contrast-to-noise ratio (CNR = mean SI lesion – mean SI liver/SD) by outlining freehand polygonal region of interest (ROIs) on the site of the hypervascular nodule and on the adjacent liver parenchyma within 2cm from the lesion on images acquired during the hepatic arterial phase by using a dedicated workstation (Extended WorkSpace eXplore, Philips, Best, The Netherlands).

Qualitative evaluation

To compare image quality between the hepatic arterial phase images acquired by the two techniques, two board-certified diagnostic radiologists with 22 and 11 years of experience in abdominal MR imaging performed independent visual assessments of image noise. They were blinded to clinical data and evaluated arterial and portal venous phase images without access to images obtained in other phases. After their independent evaluations, the reviewers assigned a score in consensus. Image noise was quantified on a 3-point scale on which a score of 3 denoted almost no or minimal image noise throughout the image; 2, a moderate degree of image noise that did not affect diagnostic utility, and 1, severe image noise that may severely hamper diagnostic utility. All readings were performed on a PACS– integrated workstation (19-inch TFT display, resolution 2560 × 1600 pixels, Ebit Sanità AET, Genoa, Italy) by using a proprietary software package (Ebit Sanità AET, Genoa, Italy).

Statistical analysis

Statistical analysis was performed using STATA, version 13 (StataCorp, Lakeway Drive, College Station, Texas, USA). We used the non-parametric correlation analysis and the intra-class correlation coefficient (ICC) to assess the agreement between test – bolus and bolus – tracking technique. Inter-observer agreement was considered as slight for an ICC of <0.21, fair for a value of 0.21–0.40, moderate for a value of 0.41–0.60, good for a value of 0.61–0.80, and optimal for a value of 0.81–1.00.

For all tests a P value < .05 was considered to indicate a statistically significant difference.

Results

Tables 1 show the results of SNR and CNR of test - bolus and bolus - tracking techniques.

Test - bolus and bolus - tracking techniques did not differ in the estimation of the correct delay time for the hepatic arterial phase at contrast-enhanced MR imaging in patients with HCC in liver cirrhosis. There was good correlation (r=0.85) and agreement (ICC=0.9) between the delay times (25-27 seconds) for the hepatic arterial phase calculated by test – bolus and bolus – tracking techniques. Test – bolus versus bolus – tracking techniques did not differ both in SNR (301.2 ± 154.54 vs. 330.77 ± 240.75; P=0.89 Mann-Whitney U test) and CNR (24.5 ± 0.512 seconds) was performed, and yielded a subtracted coronal two-dimensional projection of the abdominal aorta every second. Dynamic sequence on hepatic arterial phase began with 5 seconds delay after visualization of contrast at the abdominal aorta. Portal venous and equilibrium phase MR images were acquired with 70 seconds and 3 minutes delay from the beginning of contrast injection while hepatobiliary phase (HBP) MR images were acquired 2 hours from contrast agent injection.

Liver Pancreat Sci, 2016 doi: 10.15761/LPS.1000102

Volume 1(1): 2-4
Quaia E (2016) Test-bolus versus bolus-tracking in the timing of hepatic arterial phase at contrast-enhanced magnetic resonance imaging in patients with hepatocellular carcinoma

Table 1a. Test - Bolus data.

<table>
<thead>
<tr>
<th>Patient</th>
<th>ROI Liver</th>
<th>ROI Lesion</th>
<th>ROI Air</th>
<th>SNR</th>
<th>CNR</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>640.4 ± 96.6</td>
<td>802.4 ± 10</td>
<td>14.5 ± 17.2</td>
<td>162.4</td>
<td>11.2</td>
</tr>
<tr>
<td>2</td>
<td>809.4 ± 10.4</td>
<td>1041.1 ± 88.9</td>
<td>20.1 ± 12.8</td>
<td>171.7</td>
<td>8.54</td>
</tr>
<tr>
<td>3</td>
<td>597.5 ± 72.2</td>
<td>989.8 ± 30.9</td>
<td>1.5 ± 9.8</td>
<td>392.3</td>
<td>41.29</td>
</tr>
<tr>
<td>4</td>
<td>762 ± 32.3</td>
<td>1278.2 ± 60.9</td>
<td>14.4 ± 16.6</td>
<td>516.2</td>
<td>35.84</td>
</tr>
<tr>
<td>5</td>
<td>450.6 ± 26.6</td>
<td>760 ± 54.9</td>
<td>12.3 ± 16.8</td>
<td>309.4</td>
<td>25.15</td>
</tr>
<tr>
<td>6</td>
<td>715.9 ± 31.1</td>
<td>1020 ± 59.6</td>
<td>21.6 ± 16.8</td>
<td>304.1</td>
<td>14.48</td>
</tr>
<tr>
<td>7</td>
<td>564.1 ± 54.3</td>
<td>664.7 ± 26.3</td>
<td>14 ± 9.3</td>
<td>100.6</td>
<td>7.18</td>
</tr>
<tr>
<td>8</td>
<td>769.2 ± 65.6</td>
<td>990.2 ± 21.2</td>
<td>15.7 ± 11.8</td>
<td>221</td>
<td>14.07</td>
</tr>
<tr>
<td>9</td>
<td>201.9 ± 5.6</td>
<td>735 ± 11</td>
<td>8.5 ± 12.3</td>
<td>533.1</td>
<td>62.71</td>
</tr>
<tr>
<td>Mean ± SD</td>
<td>618.96 ± 200.42</td>
<td>920.16 ± 194.16</td>
<td>13.71 ± 3.17</td>
<td>301.2 ± 154.54</td>
<td>24.5 ± 18.74</td>
</tr>
</tbody>
</table>

Table 1b. Bolus - Tracking data.

<table>
<thead>
<tr>
<th>Patient</th>
<th>ROI Liver</th>
<th>ROI Lesion</th>
<th>ROI Air</th>
<th>SNR</th>
<th>CNR</th>
</tr>
</thead>
<tbody>
<tr>
<td>10</td>
<td>428.4 ± 80.6</td>
<td>604.2 ± 70.2</td>
<td>11.9 ± 10.3</td>
<td>175.8</td>
<td>14.77</td>
</tr>
<tr>
<td>11</td>
<td>484 ± 96.2</td>
<td>811.40 ± 17.6</td>
<td>19.6 ± 11.8</td>
<td>327.4</td>
<td>16.7</td>
</tr>
<tr>
<td>12</td>
<td>1032.7 ± 53.7</td>
<td>1270.6 ± 86.6</td>
<td>16.1 ± 22.3</td>
<td>237.9</td>
<td>14.77</td>
</tr>
<tr>
<td>13</td>
<td>1003.8 ± 37.9</td>
<td>1041 ± 92.3</td>
<td>15.1 ± 13.1</td>
<td>37.2</td>
<td>2.46</td>
</tr>
<tr>
<td>14</td>
<td>772.6 ± 28.1</td>
<td>1427 ± 28.8</td>
<td>20.5 ± 7.1</td>
<td>654.4</td>
<td>31.92</td>
</tr>
<tr>
<td>15</td>
<td>705.7 ± 61.2</td>
<td>1468.8 ± 66.3</td>
<td>16.3 ± 9.5</td>
<td>763.1</td>
<td>46.81</td>
</tr>
<tr>
<td>16</td>
<td>527.5 ± 21.6</td>
<td>636.8 ± 34.7</td>
<td>23.9 ± 18</td>
<td>109.3</td>
<td>4.57</td>
</tr>
<tr>
<td>17</td>
<td>866 ± 45.6</td>
<td>1156.5 ± 35.8</td>
<td>17.2 ± 13</td>
<td>290.5</td>
<td>16.88</td>
</tr>
<tr>
<td>18</td>
<td>276.8 ± 14.7</td>
<td>658.1 ± 13.2</td>
<td>15.7 ± 7.5</td>
<td>381.3</td>
<td>24.28</td>
</tr>
<tr>
<td>Mean ± SD</td>
<td>677.5 ± 264.7</td>
<td>1008.27 ± 343.13</td>
<td>17.37 ± 3.5</td>
<td>330.77 ± 240.75</td>
<td>19.24 ± 13.67</td>
</tr>
</tbody>
</table>

18.74 vs. 19.24 ± 13.67; P=0.89).

Discussion

The first finding of our study was that test – bolus and bolus – tracking techniques did not differ in the estimation of the correct delay time for the hepatic arterial phase at contrast-enhanced MR imaging to visualize hypervascular HCC nodules in a background of liver cirrhosis. The test – bolus and bolus – tracking techniques present a good correlation and agreement for the timing of hepatic arterial phase. Bolus chase may be applied in the place of the bolus test, for those sequences with an early filling of the center of the K-space, to calculate the correct delay time for the hepatic arterial phase at contrast-enhanced MR imaging. This study shows evidence that accurate capture of liver arterial phase can be attributed mostly to the ability of real-time bolus tracking to resolve the strong variance in contrast arrival time into the aorta.

Theoretically, test - bolus technique provides the most accurate determination of the acquisition delay time for the hepatic arterial phase. The use of fluoroscopic triggering is appropriate only for MR sequences with which the high-contrast central portion of k-space is filled first, at the beginning of the acquisition, as in the present study. Contrary to the 3D THRIVE sequences with centric K-space acquisition used in this study, conventional 3D gradient-recalled echo sequences typically employ a sequential k-space acquisition with data acquired linearly or radially over many segments while the center of k-space is passed multiple times over the scan duration. As a consequence this averages the dynamic image contrast, such that the middle of the acquisition is representative of the peak contrast on the MR images. For these methods of K-space acquisition the test – bolus technique remains the most adequate technique to be used in the calculation of the timing for the correct hepatic arterial phase in cirrhotic patients with HCC.

The second finding of the present study was the absence of difference between the SNR and CNR of HCC between test – bolus and bolus – tracking techniques. This can allow to use undifferently the two timing techniques if centric K-space acquisition is employed in dynamic contrast-enhanced MR imaging.

The main limitation of the present study is that an independent patient sample analysis was performed instead of paired data analysis with intra-individual comparison.

In conclusion test - bolus vs. bolus - tracking did not differ in the timing of hepatic arterial phase in patients with HCC.

References

Quaia E (2016) Test-bolus versus bolus-tracking in the timing of hepatic arterial phase at contrast-enhanced magnetic resonance imaging in patients with hepatocellular carcinoma

prospective randomized study in patients with chronic liver damage. *Radiology* 225: 407–415. [Crossref]


**Copyright:** ©2016 Quaia E. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.